Article Contents ::
- 1 The Brand Name RINTO Has Generic Salt :: Ranitidine
- 2 RINTO Is From Company Sienna Form. Priced :: Rs. 2.76
- 3 RINTO have Ranitidine is comes under Sub class GERD, of Main Class Gastrointestinal System
- 4 Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: GERD,
- 5 Disclaimer ::
The Brand Name RINTO Has Generic Salt :: Ranitidine
RINTO Is From Company Sienna Form. Priced :: Rs. 2.76
RINTO have Ranitidine is comes under Sub class GERD, of Main Class Gastrointestinal System
Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: GERD,
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
Drug Dose ::
Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. For prevention of NSAID-associated ulceration: 150 mg bid. Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed. Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. Prophylaxis during NSAID treatment 150 mg twice daily. IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.
Drug Precautions ::
Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.
Drug Side Effects ::
Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations. Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
Pregnancy category ::
Drug Mode of Action ::
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Drug Interactions ::
Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.